Thomas C Hanff1, Edo Y Birati2. 1. Department of Medicine Cardiovascular Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2. Department of Medicine Cardiovascular Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. edo.birati@pennmidicine.upenn.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to synthesize and summarize recent developments in the care of patients with end-stage heart failure being managed with a left ventricular assist device (LVAD) as destination therapy. RECENT FINDINGS: Although the survival of patients treated with LVAD continues to improve, the rates of LVAD-associated complication, such as right ventricular failure, bleeding complications, and major infection, remain high, and management of these patients remains challenging. The durability and hemocompatibility of LVAD support have greatly increased in recent years as a result of new technologies and novel management strategies. Challenges remain in the comprehensive care of patients with destination therapy LVADs, including management of comorbidities and optimizing patient function and quality of life.
PURPOSE OF REVIEW: The purpose of this review is to synthesize and summarize recent developments in the care of patients with end-stage heart failure being managed with a left ventricular assist device (LVAD) as destination therapy. RECENT FINDINGS: Although the survival of patients treated with LVAD continues to improve, the rates of LVAD-associated complication, such as right ventricular failure, bleeding complications, and major infection, remain high, and management of these patients remains challenging. The durability and hemocompatibility of LVAD support have greatly increased in recent years as a result of new technologies and novel management strategies. Challenges remain in the comprehensive care of patients with destination therapy LVADs, including management of comorbidities and optimizing patient function and quality of life.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: Mandeep R Mehra; Christopher Salerno; Yoshifumi Naka; Nir Uriel; Joseph C Cleveland; Douglas Horstmanshof; Daniel J Goldstein Journal: J Heart Lung Transplant Date: 2018-08-24 Impact factor: 10.247
Authors: Nir Uriel; Daniel Burkhoff; Jonathan D Rich; Stavros G Drakos; Jeffrey J Teuteberg; Teruhiko Imamura; Daniel Rodgers; Jayant Raikhelkar; Esther E Vorovich; Craig H Selzman; Gene Kim; Gabriel Sayer Journal: Circ Heart Fail Date: 2019-04 Impact factor: 8.790
Authors: Daniel Zimpfer; Martin Strueber; Philipp Aigner; Jan D Schmitto; Arnt E Fiane; Robert Larbalestier; Steven Tsui; Paul Jansz; Andre Simon; Stephan Schueler; Francesco Moscato; Heinrich Schima Journal: Eur J Cardiothorac Surg Date: 2016-09-07 Impact factor: 4.191
Authors: Colleen K McIlvennan; Jocelyn S Thompson; Daniel D Matlock; Joseph C Cleveland; Shannon M Dunlay; Shane J LaRue; Eldrin F Lewis; Chetan B Patel; Mary Norine Walsh; Larry A Allen Journal: J Cardiovasc Nurs Date: 2016 Nov/Dec Impact factor: 2.083
Authors: Jeffrey J Teuteberg; Mark S Slaughter; Joseph G Rogers; Edwin C McGee; Francis D Pagani; Robert Gordon; Eduardo Rame; Michael Acker; Robert L Kormos; Christopher Salerno; Thomas P Schleeter; Daniel J Goldstein; Julia Shin; Randall C Starling; Thomas Wozniak; Adnan S Malik; Scott Silvestry; Gregory A Ewald; Ulrich P Jorde; Yoshifumi Naka; Emma Birks; Kevin B Najarian; David R Hathaway; Keith D Aaronson Journal: JACC Heart Fail Date: 2015-10 Impact factor: 12.035
Authors: Sebastian V Rojas; Simon Junghans; Henrik Fox; Kanstantsin Lazouski; Rene Schramm; Michiel Morshuis; Jan F Gummert; Justus Gross Journal: Antibiotics (Basel) Date: 2022-04-29